Seres Therapeutics, which is developing therapies that replace beneficial colon bacteria to treat infections, raised $134 million by offering 7.4 million shares at $18.00, above the range of $15 to $17. Seres Therapeutics plans to list on the NASDAQ under the symbol MCRB. Seres Therapeutics initially filed confidentially on 12/11/2014. Goldman Sachs and BofA Merrill Lynch acted as lead managers on the deal.
